Certified by Founder Lodge
Digitalis Ventures
United States - New York, NY
INVESTOR
1 Disclosed Funding Rounds $100,000,000
32 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Digitalis Ventures is a venture capital firm that invests in solutions to complex problems in human and animal health. Digitalis partners with entrepreneurs, scientists, and inventors across
| Company | Date | Round | Raised |
|---|---|---|---|
 Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
 GRO Biosciences |
July, 23 ,2024 | Series B | $60,300,000 |
 Matchpoint Therapeutics |
October, 17 ,2022 | Series A | $100,000,000 |
 Companion |
April, 13 ,2023 | Unknown | $6,000,000 |
 Eden Brew |
May, 31 ,2022 | Unknown | $5,000,000 |
 Ascend Gene & Cell Therapies |
May, 10 ,2023 | Series A | $132,500,000 |
 Judo Bio |
October, 08 ,2024 | Seed | $100,000,000 |
 T-Therapeutics Ltd |
November, 16 ,2023 | Series A | $59,707,000 |
 Ness |
May, 11 ,2022 | Seed | $15,500,000 |
 Gallant Therapeutics |
January, 09 ,2024 | Series A | $15,000,000 |
 Switch Therapeutics |
March, 15 ,2023 | Series A | $52,000,000 |
 Ansel Health |
January, 24 ,2024 | Unknown | $20,000,000 |
| Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
 MoeGo |
March, 05 ,2024 | Series A | $24,000,000 |
| Companion |
April, 13 ,2023 | Unknown | $6,000,000 |
 Alterome Therapeutics, Inc |
April, 09 ,2024 | Series B | $132,000,000 |
| Ascend Gene & Cell Therapies |
May, 10 ,2023 | Series A | $132,500,000 |
 ELEGEN |
May, 16 ,2024 | Series B | $35,000,000 |
| T-Therapeutics Ltd |
November, 16 ,2023 | Series A | $59,707,000 |
| Gallant Therapeutics |
January, 09 ,2024 | Series A | $15,000,000 |
| GRO Biosciences |
July, 23 ,2024 | Series B | $60,300,000 |
| Ansel Health |
January, 24 ,2024 | Unknown | $20,000,000 |
| Judo Bio |
October, 08 ,2024 | Seed | $100,000,000 |
| MoeGo |
March, 05 ,2024 | Series A | $24,000,000 |
| Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
| Alterome Therapeutics, Inc |
April, 09 ,2024 | Series B | $132,000,000 |
 Galatea Bio Inc. |
March, 28 ,2025 | Unknown | $25,000,000 |
| ELEGEN |
May, 16 ,2024 | Series B | $35,000,000 |
| GRO Biosciences |
July, 23 ,2024 | Series B | $60,300,000 |
| Judo Bio |
October, 08 ,2024 | Seed | $100,000,000 |
| Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
| Galatea Bio Inc. |
March, 28 ,2025 | Unknown | $25,000,000 |
Cherry Ventures
Blue Bear Capital
Slow Ventures
Climate Capital
Eniac Ventures
BuildVision | $10,000,000 | (Mar 28, 2025)
Nanoprecise Sci Corp | $38,000,000 | (Mar 28, 2025)
Mendel | $35,000,000 | (Mar 28, 2025)
MemryX Inc. | $44,000,000 | (Mar 28, 2025)
